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THE USE OF CONTRACEPTION AS A DISEASE MANAGEMENT
TOOL IN WILDLIFE
Jack C. Rhyan, D.V.M, M.S., Lowell A. Miller, Ph.D., and Kathleen A. Fagerstone, Ph.D.

Abstract: Contraception offers potential as a tool for managing certain diseases in wildlife, most notably
venereally transmitted diseases or diseases transmitted at parturition. Brucellosis is an excellent example of an
infectious disease present in wild populations that could potentially be managed through immunocontraception.
Previous studies in bison (Bison bison) suggest that a single injection of GonaConTM (National Wildlife Research
Center, U.S. Department of Agriculture/Animal and Plant Health Inspection Service/Wildlife Services, Fort
Collins, Colorado 80521, USA) results in 3 or more yr of infertility. Ongoing studies will determine if the use of
GonaCon in bison decreases shedding of Brucella abortus from infected animals and will better define the duration
of infertility following a single injection
Key words: Bison, Brucella abortus, brucellosis, gonadotropin-releasing hormone, immunocontraception.

BRIEF COMMUNICATION
The management of diseases in wild populations presents many challenges, including those of
difficult logistics, a paucity of efficacious techniques, effective vaccine or therapeutic delivery
systems, and public acceptability. Contraception
offers potential as a disease management tool for
certain diseases, most notably venereally transmitted diseases or diseases transmitted at parturition. Brucellosis, a group of zoonotic diseases
caused by bacteria in the genus Brucella, is an
excellent example of a group of infections present
in wild populations that could potentially be
managed through immunocontraception. Swine
brucellosis, caused by Brucella suis, is transmitted
through the venereal route as well as through
contact with aborted fetuses and placental membranes and fluids. Bovine brucellosis, caused by
Brucella abortus, is transmitted among animals,
including cattle, bison (Bison bison), and elk
(Cervus elaphus), primarily through contact with
infected aborted fetuses, placentas, parturient
fluids, or postparturient uterine discharge. Additionally, the organism is shed in the milk from
infected dams and can be transmitted to calves
through suckling. Following infection, females
often abort. Subsequent pregnancies may result
in abortion or the birth of weak or normal calves
and may result in shedding of the organism. The
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occurrence of venereal transmission of brucellosis
in bison is unknown; however, based on a single
study in bison and studies in cattle, it is not
considered likely to be a significant route of
transmission.1,4,5 Therefore, transmission of disease in cattle, bison, and elk is primarily dependent on the occurrence of pregnancy and abortion
or calving of infected animals.
GonaConTM (National Wildlife Research Center, U.S. Department of Agriculture/Animal and
Plant Health Inspection Service/Wildlife Services,
Fort Collins, Colorado 80521, USA), a gonadotropin-releasing hormone (GnRH) immunocontraceptive vaccine, is approved for use in wild
white-tailed deer (Odocoileus virginianus), in which
a single injection usually results in 2 or more yr of
infertility.2 This study reports the results of three
small pilot studies examining the use of GonaCon
to prevent parturition in bison.
The first study was conducted at Northwest
Trek, a zoologic park in the state of Washington
(USA). Its purpose was to determine if the GnRH
vaccine had any effect on the reproductive success
of five breeding-age female bison (age range: 2–8
yr) as compared to the herd’s normal reproductive
history of over 60% reproduction annually. The
five bison received 1,800 lg of the vaccine by
intramuscular injection between 21 May and 26
July 2001. The animals were continuously exposed to multiple bulls. Three of the five did not
calve in 2002, one had a live calf, and one died
because of dystocia. Because of the incomplete
contraception of the group, the remaining four
bison were boosted with the same dose of vaccine
on 30 August 2002. The boosted bison did not
calve in 2003, 2004, or 2005. By 2012, at least two
of the three bison remaining alive had given birth
to one or more calves. These results suggested a
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Table 1. Results of pilot study comparing the reproductive results per year of single-dose gonadotropinreleasing hormone–vaccinated bison (1,800 lg) with nonvaccinated controls.
Treatment group

Controls
Vaccinates
a
b

2002a

2003

2004

2005

2006

2007

2008

Total calves/RYsb

5/5
4/6

4/5
0/6

4/4
0/6

1/3
0/5

2/3
0/5

3/3
0/5

2/3
0/5

16/21
0/32

4-yr-old bison were vaccinated in June 2002. 4 of 6 were in mid or late pregnancy when vaccinated.
Total number of calves produced per reproductive years of cows in the study.

high degree of vaccine efficacy in bison following
two vaccinations.
The second study, conducted from 2002 until
2008, was begun at the Idaho Department of Fish
and Game wildlife research facility in Caldwell,
Idaho (USA). The study utilized bison that were
offspring of animals that had been trapped at the
border of Yellowstone National Park in 1997 and
taken to the Idaho facility for study. In 2004, the
bison were moved to the Colorado State University, Animal Population Health Institute’s wildlife
research facility in Fort Collins, Colorado (USA).
The bison were serologically negative for brucellosis throughout the study. This study compared
reproductive results of six bison intramuscularly
vaccinated with a single dose of 1,800 lg GnRH
on 06 June 2002 to those of five sham-vaccinated
controls that received the adjuvant only. Breeding
season for bison usually begins in July and may
continue for several months. Results of the first
year of this study have been previously reported.3
Four of the vaccinees were in mid- or late-term
pregnancy when vaccinated. Results (Table 1)
indicate that the vaccine did not interfere with
reproductive success of animals in mid- and lateterm pregnancy at the time the vaccine was
administered. More importantly, a single dose of

Table 2. Results of dose-response study comparing
reproductive results per year of nonvaccinated controls
and single-shot low (1,000 lg), medium (2,000 lg), and
high (3,000 lg) doses of gonadotropin-releasing hormone vaccine in bison.

vaccine resulted in infertility in all vaccinees for
the duration of the study.
The third study, conducted from 2003 until
2008, evaluated the efficacy of GonaCon in bison
at low, medium, and high doses (1,000, 2,000, and
3,000 lg, respectively). That study was conducted
on bison purchased from a producer and was
begun at a private ranch in Gardiner, Montana
(USA). Bison were vaccinated on 20 May 2003;
controls received the adjuvant only. After 2 yr,
animals were moved to a private ranch in eastern
South Dakota (USA). The first year of the study
(2003), female bison were pastured with a bull
that was later discovered to be infertile; therefore,
the first exposure of the study animals to a fertile
bull was summer 2004, 14 mo after vaccination.
Results of that study (Table 2) indicate the vaccine
had increased efficacy at the higher dose, resulting
in 3 yr of infertility in three of four bison.
Two ongoing studies are designed to 1) evaluate
the duration of infertility in 10 vaccinated bison
that received 3,000 lg GonaCon as compared to
10 controls in a range setting; and 2) determine if
the use of GonaCon decreases shedding of B.
abortus from a group of 14 naturally infected bison
during the calving season as compared to a similar
group of nonvaccinees. If these studies confirm
the safety and efficacy of GonaCon in bison and
demonstrate its utility in reducing shedding of B.
abortus, the vaccine could provide a potential
nonlethal management tool to prevent transmission of the disease in an infected bison population.
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Treatment

Controls
Low dose
Medium dose
High dose

2004a 2005 2006 2007 2008 Calves/RYsb

0/5
0/5
0/5
0/4

5/5
2/5
3/5
0/4

4/5
3/5
2/5
1/4

2/3 NDc
2/4 ND
0/2 0/1
1/4 0/2

11/13
7/14
5/13
2/14

a
2-yr-old female bison were vaccinated in May 2003 and
were placed with breeding bull in July 2004.
b
Total number of calves produced per reproductive years of
cows in the study.
c
ND ¼ not done.
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